November 2024

NANJING, China, Nov. 6, 2024 /PRNewswire/ — On November 1, Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as “Leads Biolabs”) announced that LBL-034, a humanized bispecific T-cell engaging antibody targeting both GPRC5D and CD3 which is independently developed by Leads Bi

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: